Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial

被引：5
|
作者：
Cheung, Chee Kay [1 ,2 ]
Barratt, Jonathan [1 ,2 ]
机构：
[1] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[2] Univ Hosp Leicester NHS Trust, John Walls Renal Unit, Leicester, Leics, England
来源：
KIDNEY INTERNATIONAL | 2020年 / 98卷 / 04期
关键词：
D O I：
10.1016/j.kint.2020.05.033
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial. Crown Copyright (C) 2020, Published by Elsevier, Inc., on behalf of the International Society of Nephrology. All rights reserved.
引用
下载
收藏
页码：836 / 838
页数：4
相关论文
共 50 条
  • [1] Do STOP-IgAN results mean STOP-steroids in IgA nephropathy?
    Jullien, Perrine
    Mariat, Christophe
    Maillard, Nicolas
    NEPHROLOGIE & THERAPEUTIQUE, 2016, 12 (07): : 493 - 495
  • [2] What does STOP-IgAN tell us about how to treat IgA nephropathy?
    Rutherford, E.
    Mark, P. B.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2016, 46 (01): : 23 - 25
  • [3] Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)
    Nagy Judit
    Sagi Balazs
    Mate Judit
    Vas Tibor
    Kovacs Tibor
    ORVOSI HETILAP, 2017, 158 (49) : 1946 - 1952
  • [4] Should we really STOP treating patients with IgA nephropathy with steroids?
    Locatelli, F.
    Del Vecchio, L.
    Ponticelli, C.
    PHYSIOLOGY INTERNATIONAL, 2018, 105 (02) : 101 - 109
  • [5] Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
    Schimpf, Judith Isabel
    Klein, Till
    Fitzner, Christina
    Eitner, Frank
    Porubsky, Stefan
    Hilgers, Ralf-Dieter
    Floege, Juergen
    Groene, Hermann-Josef
    Rauen, Thomas
    BMC NEPHROLOGY, 2018, 19
  • [6] Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
    Judith Isabel Schimpf
    Till Klein
    Christina Fitzner
    Frank Eitner
    Stefan Porubsky
    Ralf-Dieter Hilgers
    Jürgen Floege
    Hermann-Josef Groene
    Thomas Rauen
    BMC Nephrology, 19
  • [7] Supportive Versus Immunosuppressive Therapy of Progressive IgA Nephropathy (STOP) IgAN trial: rationale and study protocol
    Eitner, Frank
    Ackermann, Diana
    Hilgers, Ralf-Dieter
    Floege, Juergen
    JOURNAL OF NEPHROLOGY, 2008, 21 (03) : 284 - 289
  • [8] Intensive Supportive Care plus Immunosuppression in IgA Nephropathy: Long-term Outcomes
    Rauen, Thomas
    Supsup, Stephanie Wied
    Fitzner, Christina
    Eitner, Frank
    Sommerer, Claudia
    Zeier, Martin
    Otte, Britta
    Panzer, Ulf
    Budde, Klemens
    Benck, Urs
    Mertens, Peter R.
    Kuhlmann, Uwe
    Witzke, Oliver
    Gross, Oliver
    Vielhauer, Volker
    Mann, Johannes
    Hilgers, Ralf-Dieter
    Floege, Juergen
    INTERNIST, 2020, 61 (SUPPL 1): : S54 - S55
  • [9] Long-Term Outcomes in IgA Nephropathy
    Pitcher, David
    Braddon, Fiona
    Hendry, Bruce
    Mercer, Alex
    Osmaston, Kate
    Saleem, Moin A. A.
    Steenkamp, Retha
    Wong, Katie
    Turner, A. Neil
    Wang, Kaijun
    Gale, Daniel P. P.
    Barratt, Jonathan
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (06): : 727 - 738
  • [10] LONG-TERM FOLLOW-UP OF IGA NEPHROPATHY (IGAN) DIAGNOSED IN CHILDHOOD
    WYATT, RJ
    KRITCHEVSKY, SB
    WOODFORD, SY
    MILLER, PM
    ROY, S
    HOLLAND, NH
    JACKSON, E
    BISHOF, NA
    PEDIATRIC RESEARCH, 1995, 37 (04) : A374 - A374
12345